drugset / Trial / NCT00941577

Study Evaluating the Effects of AIR645 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma

NCT00941577 ↗

Phase 2 Completed 30 enrolled Altair Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the efficacy of inhaled AIR645 in the suppression of the Asthmatic Responses in subjects with mild asthma inhaling an allergen.

Timeline

Start
2009-10
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AIR645 Unknown — Other

Indications